Livongo Health has secured $20 million in Series B funding from a few investors, including Kleiner Perkins Caufield & Byers (KPCB), DFJ and previous investor General Catalyst. The consumer digital health company will use the new funds to further develop its chronic disease management ecosystem and accelerate the adoption of its digital diabetes management program, Livongo for Diabetes, among self-insured employers, healthcare providers and payers. As part of the deal, Dr. Beth Seidenberg, General Partner at KPCB; and Emily Melton, Partner at DFJ, will be joining Livongo Health’s Board of Directors.

“We are very pleased to receive the support and insight of some of Silicon Valley’s premier healthcare investors,” said Glen Tullman, CEO of Livongo Health. “With thousands of people now using Livongo for Diabetes, it’s clear that the best way for people to manage chronic diseases like diabetes is to empower them with real-time, personalized information about their condition. This information improves care, reduces costs, and enables people to focus on their lives and not their diseases.”

The company’s flagship product, Livongo for Diabetes, is touted as the first diabetes management program that is completely mobile, digital and personalized to the user. It allows people with diabetes to effectively manage important aspects of their illness on their own, while keeping their family members and care team informed in real-time.

Livongo Health has agreements in place with self-insured employers such as Office Depot, Iron Mountain and multiple Fortune 100 companies; large healthcare providers such as Mission Health System and HealthCare Partners; as well as some of the country’s largest payers. The company recently completed a multi-year strategic agreement with health IT giant Cerner for integration and distribution to its client base.